title: Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
abstract: Sipuleucel-T is a therapeutic cancer vaccine approved for the treatment of castration- or hormone-refractory prostate cancer. Through a novel process, it activates the body's own antigen-presenting cells to induce an immune response to prostatic acid phosphatase, a protein found on prostate cancer cells. A treatment course consists of three total infusions spread 2 weeks apart. Throughout all phases of clinical trials, sipuleucel-T has been shown to be safe and well tolerated. Sipuleucel-T has demonstrated an ability to increase overall survival by approximately 4 months when compared with placebo. However, sipuleucel-T has not shown any improvement in affecting patients' time to disease progression.
authors: University of Alabama-Tuscaloosa School of Medicine, Department of Internal Medicine, University Medical Center, Box 870326, Tuscaloosa, AL 35487, USA. mjn0004@auburn.edu
authors: Marilyn N
authors: MN
authors: Bulloch
authors: Mohammed M
authors: MM
authors: Elayan
authors: Holly R
authors: HR
authors: Renfroe
mesh_terms: D000135:Acid Phosphatase; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D017027:Protein Tyrosine Phosphatases / Q000276:immunology; D014020:Tissue Extracts / Q000008:administration & dosage* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases